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Stress Doppler Echocardiography in Systemic Sclerosis
Evidence for a Role in the Prediction of Pulmonary Hypertension
Veronica Codullo,1 Roberto Caporali,1 Giovanna Cuomo,2 Stefano Ghio,1 Michele D’Alto,3
Chiara Fusetti,1 Elena Borgogno,1 Carlomaurizio Montecucco,1 and Gabriele Valentini2
Objective. Patients with systemic sclerosis (SSc)
in whom pulmonary hypertension (PH) is not suspected
have been reported to develop an inappropriate increase
of pulmonary artery systolic pressure as estimated by
Doppler echocardiography under conditions of exercise
(pulmonary artery systolic pressure under exercise).
We undertook this study to investigate whether this
increase or any other parameter detectable by stress
Doppler echocardiography has utility in predicting the
development of PH in SSc.
Methods. We enrolled a total of 170 patients with
SSc previously investigated using standard and stress
Doppler echocardiography and tissue Doppler imaging.
Each patient was evaluated at baseline and yearly for
skin and internal organ involvement. Right-sided heart
catheterization was carried out when PH was suspected.
The baseline Cochin Risk Prediction Score was calcu-
lated retrospectively.
Results. During followup, 6 patients (3.5%) devel-
oped PH. Compared with patients without any feature
suggesting PH, the Cochin Risk Prediction Score was
higher in this group (mean  SD 4.2  0.9 versus 3.4 
0.9; P < 0.05), as was the difference between pulmonary
artery systolic pressure under exercise and pulmonary
artery systolic pressure (pulmonary artery systolic
pressure) (18.2  7 mm Hg versus 9.4  6.5 mm Hg;
P < 0.001), even when adjusted for cardiac index
changes. In multivariate analysis, pulmonary artery
systolic pressure (hazard ratio [HR] 3.4 [95% confi-
dence interval 1.4–8], P < 0.01) and Cochin Risk
Prediction Score within the fifth quintile of the values
registered in our series (HR 9.3 [95% confidence inter-
val 1.4–63.7], P < 0.05) were the only factors indepen-
dently predictive of PH during followup. A pulmonary
artery systolic pressure cutoff of >18 mm Hg, identified
by receiver operating characteristic curve analysis, had
a sensitivity of 50% and a specificity of 90% for the
development of PH during followup.
Conclusion. An inappropriate response to exer-
cise among patients with SSC is detectable by stress
Doppler echocardiography. Independently of other clin-
ical associations, increased pulmonary artery systolic
pressure heralds PH. Stress Doppler echocardiography
may represent an additional screening tool for this
severe complication.
Early detection of pulmonary hypertension (PH)
is critical to ensure that patients promptly receive the
correct treatment for this severe pathophysiologic con-
dition (1). Systemic sclerosis (SSc) is a connective tissue
disorder whose natural course and prognosis are af-
fected by this pulmonary vascular complication (2),
which is indeed one of the most frequent causes of death
in SSc patients (3). Many forms of PH, as defined by a
mean pulmonary artery pressure (PAP) 25 mm Hg at
rest (1), can occur in SSc (4,5). Precapillary PH is the
most common condition (2,6), with group 1 pulmonary
arterial hypertension (PAH) (1) being relatively more
frequent than PH due to lung disease (group 3 PH [1])
or postembolic PH (group 4 PH [1]) (5). More rarely,
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postcapillary PH affects patients with left heart involve-
ment (2).
Prompt diagnosis and classification based on
hemodynamic features is crucial to improve outcomes
and to identify patients who would benefit from specific
therapies, which can dramatically change the prognosis,
especially in patients with PAH (7). Unfortunately,
early recognition of PH is still a largely unmet need in
SSc. Indeed, only a minority of patients are diagnosed
in lower New York Heart Association (NYHA) (8)
functional classes or before hemodynamic parameters
are severely compromised (9). Exercise stress tests have
been used to screen patients in the attempt to identify
early-stage PH (10–12).
We recently identified a bimodal distribution of
echocardiography-estimated pulmonary artery systolic
pressure under exercise in patients with SSc. In fact, we
detected an inappropriate increase in pulmonary artery
systolic pressure (i.e., a value 48 mm Hg under exer-
cise) in13% of 172 patients in NYHA classes I–II who
had no clinical sign or symptom of PH at study enroll-
ment (12).
The aims of the present study were to evaluate
whether an inappropriate response to exercise, or any
other parameter detected during the exercise test, can
predict the development of PH, and to compare the
performance of the parameter(s) identified with that of
the recently described Cochin Risk Prediction Score,
which consists of simple clinical observations
(age, forced vital capacity [FVC], and diffusing capacity
for carbon monoxide/alveolar volume [DLCO/VA]) and
is reported to be predictive of PH in SSc if it exceeds
2.73 (13,14).
PATIENTS AND METHODS
Patients. SSc patients consecutively attending 2 univer-
sity rheumatology units were enrolled. Written informed con-
sent was obtained from each patient, and the study was
approved by the local ethics committees. The features of these
patients are reported elsewhere (12). Inclusion in the study
required patients to be in NYHA class I or II and to have a
peak velocity of tricuspid regurgitation (VTR) of 3 meters/
second on standard echocardiography. Patients already diag-
nosed as having any form of PH were excluded. The clinical
characterization of patients at baseline and during followup
was performed according to the European League Against
Rheumatism Scleroderma Trial and Research Recommenda-
tions (15).
The following clinical and functional parameters were
considered: time of onset of Raynaud’s phenomenon and first
non–Raynaud’s phenomenon symptom, extent of skin involve-
ment (limited cutaneous or diffuse cutaneous) according to the
classification system of LeRoy et al (16), autoantibody subset,
worsening of vascular manifestation or skin involvement in
the last month, gastrointestinal symptoms (esophageal, stom-
ach, intestinal), and dyspnea and its NYHA class. Interstitial
lung disease (ILD) was diagnosed if FVC was 70% of the
predicted value or if features of bibasilar ground-glass or
reticular images were detected by high-resolution computed
tomography (HRCT) of the lung irrespective of its quantifica-
tion. Lung HRCT was performed if SSc was newly diagnosed at
the time of inclusion in the study or if pulmonary function
testing suggested ILD. Each patient was investigated at base-
line and yearly for skin and organ involvement. The baseline
Cochin Risk Prediction Score was calculated retrospectively
using the following formula: [0.0001107 age] [0.0207818
(100  FVC)]  [0.04905  (150  DLCO/VA)] (13).
During longitudinal analysis, patients were referred for
right-sided heart catheterization (RHC) if, at the followup
visit, any sign or electrocardiogram findings suggestive of PH
were detected or if the estimated systolic PAP was40 mm Hg
on followup echocardiography, or if DLCO was 55% of the
predicted value in association with an FVC 70% of the
predicted value (4). Physicians caring for the patients were
blinded with regard to stress echocardiography results includ-
ing pulmonary artery systolic pressure under exercise. On
RHC, PH was defined as mean PAP 25 mm Hg and, on the
basis of other hemodynamic parameters, was subgrouped
according to current guidelines (1).
Echocardiography at rest and under exercise. Basal
and stress echocardiography and tissue Doppler imaging were
performed at both centers as previously described (12). Briefly,
pulmonary artery systolic pressure was calculated by adding a
right atrial pressure estimate to the peak VTR (right atrial
pressure estimate was always considered 5 mm Hg both at
baseline and during followup studies). Left ventricular (LV)
peak early (E) and late (A) diastolic velocities were measured
using tissue Doppler imaging at the level of the lateral mitral
annulus. Cardiac index (CI) changes were recorded during
exercise to adjust the increase in pulmonary artery systolic
pressure (pulmonary artery systolic pressure/CI). Doppler-
estimated cardiac output was derived from the Doppler-
estimated stroke volume using the velocity time integral of
flow through the LV outflow tract, the diameter of the LV
outflow tract, and the heart rate recorded during the imaging
study. All data were analyzed by 2 observers (SG and MD) who
were blinded with regard to patient data.
Statistical analysis. Continuous and categorical vari-
ables were collected and analyzed with Microsoft Excel and
Stata software. Continuous variables are expressed as the
mean 	 SD or the median (interquartile range [IQR]) accord-
ing to distribution. Categorical data are expressed as absolute
and relative frequencies (numbers and percentages). Differ-
ences between groups were tested with parametric tests (for
normally distributed variables), nonparametric tests (for non-
normally distributed variables), univariate tests, and multi-
variate tests, as appropriate. Receiver operating characteristic
(ROC) curves and the area under the curve (AUC) method
were applied to estimate sensitivity and specificity at different
cutoffs to detect PH. Overall accuracy was measured by the
AUC and reported with 95% confidence intervals. Survival was
evaluated with Kaplan-Meier curves, and differences between
groups were tested with the log rank method. The primary
outcome for investigation was PH development. Observation
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was censored at the time of the last available clinical assess-
ment. The Cox regression model was used for multivariate
analysis of survival and to investigate hazard ratios (HRs).
Besides raw data analysis, to increase the precision of our
analyses, missing data on predictors were imputed using
switching regression, an iterative multivariate regression tech-
nique that retains an element of random variation in the
estimates (17). Using multiple imputation of predictors, 170
subjects were finally available for all the adjusted analyses.
Two-sided P values less than 0.05 were considered significant.
RESULTS
Patient characteristics. Complete baseline and
followup data were available for 170 patients. Table 1
shows demographic and clinical data according to the
main disease subsets, limited cutaneous SSc (lcSSc) and
diffuse cutaneous SSc (dcSSc). Mean FVC and DLCO
were significantly lower in the patients with dcSSc
(P  0.001 and P  0.05, respectively); this was prob-
ably due to the more frequent occurrence of ILD in
this group (P  0.001). DLCO/VA values were similar in
the 2 subsets (Table 1). Only FVC (odds ratio [OR]
0.96 [95% confidence interval 0.94–0.98], P  0.01) and
the presence of anti–topoisomerase I antibodies (OR 2.5
[95% confidence interval 1–6.3], P  0.05) were inde-
pendently associated with ILD in a model that also
included age, cutaneous subset, and DLCO.
The mean 	 SD Cochin Risk Prediction Score in
the whole sample was 3.4 	 0.9, and it was significantly
higher in patients with dcSSc. A total of 118 patients had
a Cochin Risk Prediction Score above the cutoff of 2.73.
Patients in the highest Cochin Risk Prediction Score
quintile (n 
 30) had scores of 4.18.
Clinical association of the stress echocardio-
graphic response. Details of basal echocardiographic
features and the response to stress exercise in these
patients are reported elsewhere (12). The ergometric
test revealed a significant increase of pulmonary artery
systolic pressure under exercise in our SSc patients
compared to basal values on standard echocardiography
(mean 	 SD 24 	 8 mm Hg versus 36 	 9 mm Hg;
P  0.001). Of the functional and SSc clinical variables
analyzed in relation to the stress echocardiographic
response, only ILD was associated with higher pul-
monary artery systolic pressure and pulmonary artery
systolic pressure under exercise, which is in accord-
ance with findings of a previous study (12). There
was a significant correlation between at-rest and post-
exercise estimates (r 
 0.9, P  0.01). Consequently,
for statistical analyses, pulmonary artery systolic pres-
sure under exercise was corrected for basal pulmonary
artery systolic pressure and expressed as the difference
(pulmonary artery systolic pressure).
In a multivariate analysis that included variables
such as interstitial involvement, age, disease duration,
disease subset, autoantibody subgroups, and E:A ratio
1 (for diastolic dysfunction) to assess major deter-
minants of the stress echocardiographic response,
pulmonary artery systolic pressure was significantly
related only to the presence of ILD (adjusted coefficient
3.6, SE 1.35, P  0.01). pulmonary artery systolic
pressure values corrected for changes in CI during
exercise (pulmonary artery systolic pressure/CI) were
higher in patients with dcSSc (median [IQR] mm Hg/
liter/minute/m2 5.6 [2.6–9.2], versus 3.4 [1.6–5.8] in
patients with lcSSc; P  0.05) and in those with ILD
(median [IQR] mm Hg/liter/minute/m2 5.1 [0–18.8],
versus 2.9 [0–16] in those without ILD), but the cor-
rected effect on the variable resulted in significance only
for ILD (adjusted coefficient 1.8, SE 0.8, P  0.01)
when, again, a multivariate analysis included both inter-
Table 1. Clinical features of the patients according to the 2 major subsets of SSc*
Total
(n 
 170)
lcSSc
(n 
 138)
dcSSc
(n 
 32) P
Age, mean 	 SD years 55.2 	 13 55.4	 12.9 55	 13.6 NS
No. of men/women 17/153 15/123 2/30 NS
No. ANA negative/ACA positive/anti–topo I positive 7/77/60 7/77/34 0/0/26 0.001
Disease duration, median (IQR) years 7.4 (3.2–12) 7.8 (3.1–12) 6.7 (3.5–15) NS
MRSS, median (IQR) 4 (1–8) 3 (0–5) 14 (4–21) 0.001
ILD, no. (%) 72 (42) 47 (34) 25 (78) 0.001
FVC, mean 	 SD % of predicted 102 	 21 105 	 19 90 	 23 0.001
DLCO, mean 	 SD % of predicted 76 	 20 78 	 19 67 	 23 0.012
DLCO/VA, mean 	 SD % of predicted 79 	 18 80 	 17 74 	 19 NS
Cochin Risk Prediction Score, mean 	 SD 3.4 	 0.9 3.3 	 0.8 3.9	 1 0.001
* SSc 
 systemic sclerosis; lcSSc 
 limited cutaneous SSc; dcSSc 
 diffuse cutaneous SSc; NS 
 not significant; ANA 
 antinuclear antibody;
ACA 
 anticentromere antibody; anti–topo I 
 anti–topoisomerase I; IQR 
 interquartile range; MRSS 
 modified Rodnan skin thickness score;
ILD 
 interstitial lung disease; FVC 
 forced vital capacity; DLCO 
 diffusing capacity for carbon monoxide; DLCO/VA 
 DLCO/alveolar volume.
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stitial lung and skin involvement to predict pulmonary
artery systolic pressure/CI values.
SSc patients were divided into 2 groups: those
with a pulmonary artery systolic pressure under exercise
value below the previously defined cutoff of 48 mm Hg
(group 1; n
 149) and those with a value at or above the
cutoff (group 2; n
 21). Patients in the 2 groups did not
differ in terms of sex or SSc subset. Anticentromere
antibodies were more frequent in group 1 (Table 2), but
this association was no longer relevant when adjusted for
cutaneous involvement (not shown). Similarly, there was
no statistically significant difference in age, disease
duration, modified Rodnan skin thickness score (MRSS)
(18), FVC (% of predicted value), DLCO (% of predicted
value), or DLCO/VA (% of predicted value) in the
univariate analysis (Table 2). The mean Cochin Risk
Prediction Score also did not differ between the 2
groups. The presence of ILD tended to be more fre-
quent in the group with pulmonary artery systolic pres-
sure under exercise 48 mm Hg than in the group with
a lower pulmonary artery systolic pressure under exer-
cise (62% versus 39%; P 
 0.053). ILD was again
significantly predictive of pulmonary artery systolic pres-
sure under exercise of 48 mm Hg (OR 10 [95%
confidence interval 1.4–70.4], P 0.05) in a multivariate
logistic regression analysis with correction for the effect
of disease subset, age, sex, disease duration, DLCO (% of
predicted value), E:A ratio, and autoantibody status.
PH development during followup. During a
mean 	 SD followup of 3.5 	 0.2 years, 9 patients
were referred for RHC, 5 in group 1 and 4 in group 2
(3.4% versus 19%; P  0.01). Mean 	 SD pulmonary
Table 3. Baseline features of the patients with complete followup who did not develop PH and those who did develop PH*
SSc without features of PH
(n 
 164)
SSc with PH
(n 
 6) P
Age, mean 	 SD years 55 	 13 59 	 13 NS
No. of men/women 17/147 0/6 NS
No. with lcSSc/dcSSc 132/32 6/0 NS
No. ANA negative/ACA positive/anti–topo I positive 7/73/58 0/4/2 NS
Disease duration, median (IQR) years 7.3 (3–12) 10 (7–11.5) NS
ILD, no. (%) 95 (58) 3 (50) NS
FVC, mean 	 SD % of predicted 102 	 21 107	 24 NS
DLCO, mean 	 SD % of predicted 77 	 19 53	 24 0.01
DLCO/VA, mean 	 SD % of predicted 80 	 17 62 	 15 0.05
Cochin Risk Prediction Score, mean 	 SD 3.4	 0.9 4.2 	 0.9 0.05
PASP, mean 	 SD mm Hg 23.7 	 8.1 29.5	 5.5 NS
ePASP, mean 	 SD mm Hg 33.1 	 12.6 47.7	 12.2 0.01
PASP, mean 	 SD mm Hg 9.4 	 6.5 18.2 	 7 0.001
PASP/CI, median (IQR) mm Hg/liter/minute/m2 3.5 (1.7–5.9) 10.9 (3.2–15.5) 0.05
* PH 
 pulmonary hypertension; PASP 
 pulmonary artery systolic pressure; ePASP 
 PASP under exercise; PASP 
 ePASP  PASP; CI 

change in cardiac index (see Table 1 for other definitions).
Table 2. Features of the patients with ePASP 48 mm Hg and those with ePASP 48 mm Hg*
ePASP 48 mm Hg
(n 
 149)
ePASP 48 mm Hg
(n 
 21) P
Age, mean 	 SD years 55.4 	 13 54.1	 13.7 NS
No. of men/women 16/133 1/20 NS
No. with lcSSc/dcSSc 123/26 15/6 NS
No. ANA negative/ACA positive/anti–topo I positive 4/70/53 3/7/7 0.001
Disease duration, median (IQR) years 7.2 (3–12.3) 10 (6.7–18) NS
MRSS, median (IQR) 6 (0–13) 3 (0–5) NS
ILD, no. (%) 59 (39) 13 (62) NS
FVC, mean 	 SD % of predicted 103 	 21 96	 21 NS
DLCO, mean 	 SD % of predicted 76 	 20 75 	 21 NS
DLCO/VA, mean 	 SD % of predicted 78 	 17 87 	 17 NS
Cochin Risk Prediction Score, mean	 SD 3.4 	 0.9 3.2	 0.8 NS
PASP, mean 	 SD mm Hg 8.27 	 5.6 20	 5.2 0.001
PASP/CI, median (IQR) mm Hg/liter/minute/m2 3.1 (1.6–5.5) 8.5 (5.8–10.7) 0.001
* ePASP 
 pulmonary artery systolic pressure under exercise; PASP 
 ePASP  PASP; CI 
 change in cardiac index (see Table 1 for other
definitions).
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artery systolic pressure measured by standard echocar-
diography was significantly higher and mean 	 SD
DLCO and DLCO/VA were significantly lower in these
patients than in those not undergoing RHC (43 	 7 mm
Hg versus 21 	 11 mm Hg; P  0.01 and 62 	 27% of
predicted value versus 77	 19% of predicted value; P
0.05 and 65 	 16% of predicted value versus 80 	 17%
of predicted value; P 0.01, respectively), while FVC or
the Cochin Risk Prediction Score did not differ between
groups. Overall, 6 of 170 patients (3.5%) developed PH
as defined by a mean PAP of25 mm Hg. Group 1 PAH
was confirmed in 3 patients, 1 patient had group 3
precapillary PH, and in 2 patients PH was due to left
heart disease (group 2) (1). The main clinical features
of these patients at baseline are detailed in Table 3.
Mean DLCO or DLCO/VA, Cochin Risk Prediction Score,
pulmonary artery systolic pressure under exercise,
pulmonary artery systolic pressure, and pulmonary
artery systolic pressure/CI measured upon study en-
rollment differed significantly between patients who
Figure 1. Univariate survival curves (representing survival without development of pulmonary hypertension) according to whether the Cochin Risk
Prediction Score (rps5th) was or was not in the fifth quintile (0 
 no, 1 
 yes) (A) or according to the change in pulmonary artery systolic pressure
(PASP), equal to PASP under exercise  PASP (0 
 18 mm Hg, 1 
 18 mm Hg) (B), and for different combinations of the 2 parameters
(RPSecho) (0 
 neither parameter present, 1 
 either parameter present, 2 
 both parameters present) (C).
Table 4. HRs (univariate, adjusted, and with multiple imputation adjustment) for PH development during followup*
Variable
Univariate HR
(95% CI)
(n 
 170) P
Adjusted HR
(95% CI)
(n 
 152) P
Multiple imputation
adjusted HR (95% CI)
(n 
 170) P
PASP (5 mm Hg increase)† 2.4 (1.2–4.8) 0.010 3.4 (1.4–8) 0.007 3.1 (1.4–7) 0.006
PASP/CI† 1.3 (1.1–1.5) 0.002 1.3 (1.04–1.6) 0.018 1.3 (1.05–1.6) 0.015
Cochin Risk Prediction Score, fifth quintile‡ 9.5 (1.7–52.4) 0.010 9.3 (1.4–63.7) 0.022 9.9 (1.4–70.5) 0.022
ePASP 48 mm Hg† 6 (1.2–30) 0.030 12 (0.7–223) NS 6.5 (0.5–77.9) NS
* HR 
 hazard ratio; 95% CI 
 95% confidence interval; NS 
 not significant (see Table 3 for other definitions).
† Adjusted for presence of interstitial lung disease, autoantibody status, ratio of left ventricular peak early:peak late diastolic velocities, or fifth
quintile of Cochin Risk Prediction Score (yes or no).
‡ Adjusted for PASP (5 mm Hg increase).
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subsequently developed PH and patients who were free
of this complication at the end of followup (Table 3);
notably, however, basal pulmonary artery systolic pres-
sure values did not distinguish between patients with and
those without PH at the end of followup.
PH developed in a significantly higher proportion
of patients in the fifth quintile of Cochin Risk Prediction
Score (13% of patients, versus 2% in the other quintile
groups; P  0.05). Notably, a Cochin Risk Prediction
Score of 2.73 did not predict PH (4% of patients with
a Cochin Risk Prediction Score of 2.73 developed PH,
versus 3% of patients with a Cochin Risk Prediction
Score of 2.73; P 
 1). At the time of RHC referral or
at the last followup visit, DLCO was significantly lower in
patients with PH than in those without (mean 	 SD
55.8 	 11.7% of predicted value versus 72.9 	 18.2% of
predicted value; P  0.05); although the difference did
not reach statistical significance, DLCO/VA was also
lower in PH patients (67.7 	 16.2% of predicted value
versus 78.6 	 17% of predicted value) (further informa-
tion is available upon request from the corresponding
author). Kaplan-Meier curves revealed poorer PH-free
survival in patients in the fifth quintile of Cochin Risk
Prediction Score (P  0.01) (Figure 1A). PH developed
more frequently in patients with pulmonary artery sys-
tolic pressure under exercise of 48 mm Hg on stress
echocardiography (14% of patients, versus 2% of pa-
tients with pulmonary artery systolic pressure under
exercise 48 mm Hg; P  0.05) and was associated with
increased pulmonary artery systolic pressure or
pulmonary artery systolic pressure/CI values.
Multivariate Cox regression analysis showed that
an increase in these echocardiographic estimates and
inclusion in the highest quintile of Cochin Risk Predic-
tion Score significantly predicted PH-free survival and
were the only parameters associated with a significant
and independent fold increase in HR for the develop-
ment of PH after adjustment for potential confounders
(the presence of ILD, autoantibody status, and E:A
ratio) (Table 4). In particular, after adjustment for other
confounders, pulmonary artery systolic pressure under
exercise 48 mm Hg did not retain its association with
PH development, whereas both pulmonary artery sys-
tolic pressure (or pulmonary artery systolic pressure/
CI) and being in the fifth quintile of Cochin Risk
Prediction Score showed significant HRs for PH.
Based on these results, we carried out an ROC
curve analysis to identify the pulmonary artery systolic
pressure value that could identify patients with an
increased risk of PH during followup. The ROC curve
for pulmonary artery systolic pressure (Figure 2)
showed that a cutoff of 18 mm Hg had a sensitivity of
50% and a specificity of 90% in identifying patients
who subsequently developed PH (AUC 0.82 [95% con-
fidence interval 0.7–0.95], P  0.01). Upon enrollment
in the study, 19 patients (11%) had pulmonary artery
systolic pressure 18 mm Hg. No association with any
other rheumatologic clinical feature (ILD, disease sub-
set, E:A ratio, etc.) was demonstrated in this group of
patients. The mean 	 SD Cochin Risk Prediction Score
in these patients was 3.33	 0.83, versus 3.39	 0.9 in the
rest of the population (P 
 0.3). The majority of them
(84%) had Cochin Risk Prediction Score values below
the fifth quintile. The percentage of patients with PH
upon completion of followup was significantly higher in
the group with pulmonary artery systolic pressure 18
mm Hg (16% versus 2%; P  0.05). PH-free survival
curves were worse in patients with pulmonary artery
systolic pressure 18 mm Hg (P  0.05) or with the
combination of this condition and having a Cochin Risk
Prediction Score in the fifth quintile (Figures 1B and C).
In detail, in our PH case series, 2 of 6 patients
(33%; 1 with PAH, 1 with group 3 PH) both had Cochin
Risk Prediction Scores in the fifth quintile and showed
pulmonary artery systolic pressure 18 mm Hg during
stress echocardiography. Two of 6 patients (33%; 1 with
PAH, 1 with group 2 PH) only had Cochin Risk Predic-
tion Scores in the fifth quintile. One of 6 patients (17%;
with group 2 PH) only had pulmonary artery systolic
Figure 2. Receiver operating characteristic curve for the level of
change in pulmonary artery systolic pressure (PASP), equal to PASP
under exercise  PASP, that would best predict development of pul-
monary hypertension (area under the curve [AUC] 0.82 [95% con-
fidence interval 0.7–0.95], P  0.01). Diagonal line indicates
AUC 
 0.5.
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pressure 18 mm Hg. Finally, 1 patient (17%; with
PAH) was not identified by either feature.
DISCUSSION
Thus far, the role of stress echocardiography in
predicting PH in SSc patients has been investigated
only in cross-sectional studies. Steen et al (10) evaluated
whether exercise echocardiography could identify pa-
tients who might have PH in an SSc patient population
with symptoms suggesting that they were at risk for
PH. Those authors found that during exercise, 17 of 21
patients (81%) with an increase in pulmonary artery
systolic pressure under exercise of 20 mm Hg from
resting values (pulmonary artery systolic pressure) had
PH confirmed by RHC. However, in only 4 of these 17
patients (19% of the total of 21 patients) was the mean
PAP 25 mm Hg at rest, whereas the other patients
fulfilled the definition of exercise PH of a mean PAP of
30 mm Hg after exercise; the use of this definition is
not supported by current evidence-based guidelines (1).
In their cross-sectional multicenter study, Gru¨nig et al
(11) investigated the potential of stress echocardiogra-
phy to identify hypertensive responses to exercise or
hypoxia in relatives of patients with idiopathic or familial
PAH. They found that more relatives with idiopathic
or familial PAH than healthy controls had a VTR of
3.08 meters/second (which corresponds to an esti-
mated pulmonary artery systolic pressure of 43 mm
Hg), and that relatives had significantly higher mean
pulmonary artery systolic pressure under exercise or
pulmonary artery systolic pressure (mean	 SD 39.5	
5.6 mm Hg versus 35.5 	 5.4 mm Hg and 18.8 	 10.6
mm Hg versus 15.2 	 7.1 mm Hg, respectively) (11).
The present study is the first longitudinal study to
investigate the role of basal stress echocardiography in
predicting the development of PH in SSc outpatients in
NYHA class I or II without clinically suspected PH at
baseline and with pulmonary artery systolic pressure
within normal limits. We previously reported that SSc
patients had significantly higher estimated pulmonary
artery systolic pressures under exercise than did healthy
controls and that values were higher in patients with
ILD and/or LV filling abnormalities (12). In the present
study we slightly modified the definition of ILD in our
cohort in order to better ascertain the influence of even
small interstitial changes on the development of hyper-
tensive changes of the pulmonary vasculature. We con-
firmed the previous finding of an association of ILD
with higher stress pulmonary artery responses at the
baseline evaluation. ILD is thus an important variable,
which we included in the PH survival model. In the first
study (12), we also identified a subset of patients who
reacted to exercise stress with a very high pulmonary
artery systolic pressure (48 mm Hg). Longitudinal
study of our cohort revealed that, by univariate analysis,
PH-free survival was lower in patients with pulmonary
artery systolic pressure under exercise of 48 mm Hg.
Multivariate analysis of the followup data showed
that the difference versus basal values of estimated pres-
sures (pulmonary artery systolic pressure) rather than
the absolute pulmonary artery systolic pressure under
exercise or pulmonary artery systolic pressure under
exercise 48 mm Hg was predictive of the development
of PH. Indeed, mm Hg increases in pulmonary artery
systolic pressure conferred a significantly higher risk of
PH development independent of other clinical predic-
tors, such as ILD. Importantly, this was also true when
pulmonary artery systolic pressure was related to CI
changes during exercise, in the attempt to correct the
rise in pressure for adjustments of the vascular reserve,
a ratio that is clearly unbalanced in SSc (12).
In an ROC curve analysis, we found that pul-
monary artery systolic pressure increase and values 18
mm Hg were highly specific for PH development in our
cohort. Notably, this value is consistent with those
indicating a positive stress echocardiography test result
(15 or 20 mm Hg) in previous cross-sectional studies
that also focused on the pulmonary artery systolic
pressure changes during exercise rather than on their
absolute value under stress (10,11,19,20). Despite the
fact that the AUC of the ROC curve was significant,
the sensitivity of our cutoff was rather low (50%), and
this represents a limitation of our analysis. Moreover, it
should be taken into account that there could be some
misclassification bias in our study given that, for ethical
and economic reasons, RHC was not systematically
performed on all patients, but rather was performed
only if recommended by clinicians who were blinded
with regard to exercise echocardiography findings. With-
out RHC data on all patients one cannot formally
exclude the possibility that in some patients, PH, though
first detected during followup and recorded as inci-
dent, may have in fact been present prior to study
enrollment. However, the study was designed to assess
the predictive value of stress echocardiography results
in a real-life SSc cohort screened for PH according to
standard recommendations (4). In addition, exercise
echocardiography was not repeated longitudinally dur-
ing followup. Future studies might clarify which
pulmonary artery systolic pressure values should be
used to interpret exercise test results and define indica-
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tions and cost-effectiveness for performing exercise test-
ing in SSc.
From a pathophysiologic viewpoint, both pul-
monary artery systolic pressure under exercise and the
pulmonary artery systolic pressure:CI ratio probably
depend mainly on the inability of the SSc pulmonary
vascular bed to dilate under exercise and consequently
would reflect the peculiar stiff vascular system charac-
teristic of SSc (21). From a clinical point of view, our
data suggest that this inability, when exceeding a defined
value, is predictive of PH during followup.
The outcome predictive measure we identified
did not distinguish between PH groups due to the low
numbers of events that were observed in the relatively
short followup period, and this may be another limita-
tion of the study. The recently described Cochin Risk
Prediction Score for PH, based on simple clinical fea-
tures (age, DLCO/VA, and FVC) (13), was proposed
and validated for all PH groups combined, as a single
outcome.
The absolute Cochin Risk Prediction Score val-
ues in our cohort were somewhat higher than in the
patients described by Meune et al, with a mean value
that was well above their cutoff for PH (2.73) and
comparable to that in high-risk patients (mean 	 SD
3.57 	 0.45) in the original derivation cohort (13). This
discrepancy limits the application of Cochin Risk Pre-
diction Score absolute values and might be due to the
fact that, although we excluded subjects who already had
features known to predict PH risk, our study was con-
ducted in only 2 referral centers from a single country.
Nevertheless, by calculating specific cutoffs based on
the variable distribution and distinguishing patients
in the fifth quintile of Cochin Risk Prediction Score, as
also done by Meune and coworkers (13), our longitudi-
nal analysis confirmed that this feature was significantly
associated with development of PH. Moreover, the
univariate cumulative 3-year survival rates we observed
were strikingly similar to those obtained by Meune et al
(13), which, in both studies, were significantly worse in
the subgroup of patients in the fifth quintile of the
Cochin Risk Prediction Score.
In this respect, exercise echocardiography con-
tributed to the prediction of PH development indepen-
dent of classification by Cochin Risk Prediction Score.
In fact, the majority of patients (84%) identified by the
18 mm Hg cutoff in the test were not in the fifth quintile
of the Cochin Risk Prediction Score distribution, pro-
viding an additional tool to identify SSc patients at risk
of otherwise unsuspected PH. Accordingly, in our mul-
tivariate analysis of PH-free survival, pulmonary artery
systolic pressure and Cochin Risk Prediction Score in
the fifth quintile conferred significant and independent
risks of PH that even worsened PH survival curves when
present together. Nonetheless, while our findings sup-
port the significant contribution of the Cochin Risk
Prediction Score in PH risk stratification, our study is
limited by a relatively short followup period as men-
tioned above, and highlights the need for further inves-
tigation to identify absolute values to facilitate the
application of the Cochin Risk Prediction Score in daily
clinical practice.
A further limitation of the present study is that
Doppler echocardiography and tissue Doppler imaging
at rest and particularly after exercise are critically oper-
ator dependent and therefore should be performed by
dedicated and expert cardiologists in referral centers,
and this may not be accessible to every patient with SSc.
In any event, PH is a common finding in SSc (22), and
given the complexity of this pathophysiologic condition
and its various etiologies, expert management is recom-
mended to obtain a proper diagnosis and eventual
therapy in a relatively early phase of the clinical picture.
Recently, after our manuscript was submitted,
Kovacs et al pointed out that 10 patients with a marked
baseline exercise-induced increase in PAP experienced a
significant increase in mean PAP (evaluated by RHC),
both at rest and during exercise, over 1 year and that
such changes were attenuated by a subsequent 6-month
treatment with bosentan (23). Our results would ques-
tion the usefulness of PAH therapy for each SSc patient
with a marked baseline exercise-induced increase in
PAP. Actually, of our 6 patients who developed PH
during followup, 1 presented with PAH associated with
ILD, in which this drug is not recommended, and 2
developed PH secondary to left heart involvement, in
which this drug is contraindicated (1).
In conclusion, we found that PH during followup
is significantly associated with pulmonary artery sys-
tolic pressure (or with pulmonary artery systolic
pressure/CI) and with a Cochin Risk Prediction Score
within the highest quintile of values detected in our SSc
patients, and that a pulmonary artery systolic pressure
of 18 mm Hg is significantly associated with the
development of PH during followup. Herein we demon-
strate that, given its independent effect in the longitudi-
nal detection of PH in SSc patients, the Doppler echo-
cardiographic exercise test can effectively complement
clinical observations. Consequently, stress Doppler echo-
cardiography might have a role in augmenting the
efficacy of screening algorithms and detection programs
2410 CODULLO ET AL
(24) identifying a group at increased risk of developing
PH.
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